Search - tctmd.com

Displaying 461 - 480 of 909

Sort: Relevancy | Date

Presentation TTT 2018

Should we revascularized CTO lesions? Decision CTO vs Euro CTO trial

Presenter: Alfredo R. Galassi

January 14, 2018

Presentation Controversies and Advances 2017

FFR is the Gold Standard For Revascularization Decision Making

Presenter: Matthew J. Price

November 17, 2017

Presentation Controversies and Advances 2017

FFR is NOT the Gold Standard for Revascularization Decision Making

Presenter: Paul S. Teirstein

November 17, 2017

Presentation TCT 2017

TAVR in AS Patients With Stable Coronary Disease: Evolving Treatment Issues (When to Consider CABG, Timing of PCI, and Completeness of Revascularization)

Presenter: Torsten P. Vahl

November 01, 2017

Presentation TCT 2017

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Vasim Farooq

November 01, 2017

Presentation TCT 2017

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Frederick Feit

November 01, 2017

Presentation TCT 2017

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Presenter: David J. Maron, Alan C. Yeung, Jung-Min Ahn

November 01, 2017

Presentation TCT 2017

Should Pre-Diabetes Affect Revascularization Decisions?

Presenter: David J. Maron, Alan C. Yeung, Clemens von Birgelen

November 01, 2017

Presentation TCT 2017

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

Presenter: David J. Maron, Alan C. Yeung, Michael E. Farkouh

November 01, 2017

Presentation TCT 2017

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung

November 01, 2017

Presentation TCT 2017

Is There a Preferred Stent for the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Upendra Kaul

November 01, 2017

Presentation TCT 2017

When Should PCI Be Preferred in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Sripal Bangalore

November 01, 2017

Presentation TCT 2017

Should a Hybrid Revascularization Strategy for Left Main Disease Be Considered?

Presenter: James B. Hermiller Jr., John D. Puskas

November 01, 2017

Presentation TCT 2017

When Should CABG Be Preferred in the Diabetic Patient?

Presenter: David J. Maron, Alan C. Yeung, Jack Boyd

November 01, 2017

Presentation TCT 2017

Debate: EXCEL and NOBLE Prove That PCI Is Still Far From Being an Acceptable Alternative to CABG for Left Main Revascularization, With the Exception of a Small Proportion of Patients!

Presenter: Evald H. Christiansen, Erick Schampaert, John D. Puskas

October 31, 2017

Presentation TCT 2017

Debate: Based on EXCEL and NOBLE, PCI Should Become Class IA for Left Main Revascularization If Technically Feasible, at Least in Intermediate and Low SYNTAX Score Patients!

Presenter: Evald H. Christiansen, Erick Schampaert, Marco V. Wainstein

October 31, 2017

Presentation TCT 2017

Left Main Case(s) #7: Rationale and Feasibility of Bioresorbable Scaffolds

Presenter: Kenneth Chin, Nicholas J. Lembo, Bernardo Cortese

October 31, 2017

Presentation TCT 2017

Left Main Case(s) #3: My Best DK-Crush Cases

Presenter: Kenneth Chin, Nicholas J. Lembo, James B. Hermiller Jr.

October 31, 2017

Advertisement

Should we revascularized CTO lesions? Decision CTO vs Euro CTO trial

FFR is the Gold Standard For Revascularization Decision Making

FFR is NOT the Gold Standard for Revascularization Decision Making

TAVR in AS Patients With Stable Coronary Disease: Evolving Treatment Issues (When to Consider CABG, Timing of PCI, and Completeness of Revascularization)

Case #2 Conclusion: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How We Treated

Case #3 Introduction: A Symptomatic Diabetic Patient With Chronic Kidney Disease and 3-Vessel Disease How Should We Treat?

Case #2 Introduction: An Asymptomatic Diabetic Patient With Normal Exercise Tolerance and Multivessel Disease How Should We Treat?

Case #1 Conclusion: A Diabetic Patient With Left Main Disease How We Treated

Case #1 Introduction: A Diabetic Patient With Left Main Disease How Should We Treat?

Should Pre-Diabetes Affect Revascularization Decisions?

Current State-of-the-Art Diabetes Medical Management and Novel Therapies in Clinical Trials

When Is Medical Therapy the Best Choice in the Diabetic Patient?

Is There a Preferred Stent for the Diabetic Patient?

When Should PCI Be Preferred in the Diabetic Patient?

Should a Hybrid Revascularization Strategy for Left Main Disease Be Considered?

When Should CABG Be Preferred in the Diabetic Patient?

Debate: EXCEL and NOBLE Prove That PCI Is Still Far From Being an Acceptable Alternative to CABG for Left Main Revascularization, With the Exception of a Small Proportion of Patients!

Debate: Based on EXCEL and NOBLE, PCI Should Become Class IA for Left Main Revascularization If Technically Feasible, at Least in Intermediate and Low SYNTAX Score Patients!

Left Main Case(s) #7: Rationale and Feasibility of Bioresorbable Scaffolds

Left Main Case(s) #3: My Best DK-Crush Cases

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content